| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Mucin-1|MUC-1|Breast carcinoma-associated antigen DF3|Cancer antigen 15-3|CA 15-3|Carcinoma-associated mucin|Episialin|H23AG|Krebs von den Lungen-6|KL-6|PEMT|Peanut-reactive urinary mucin|PUM|Polymorphic epithelial mucin|PEM|Tumor-associated epithelial membrane antigen|EMA|Tumor-associated mucin|Mucin-1 subunit alpha|MUC1-NT, MUC1-alpha|Mucin-1 subunit beta|MUC1-beta|MUC1-CT|MUC1|PUM |
| Assay Time | |
| Detection Method | |
| Detection Range | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples |
| Sensitivity | |
| Species | |
| Storage | |
| Target | |
| UniProt # |
Background
human MUC-1 (Mucin-1) is a molecular target commonly studied in cancer and immunology research. Many proteins are studied as molecular readouts that can change with cellular state, tissue remodeling, or stress responses.
Biological role and mechanism
The biological role of MUC-1 is typically understood in terms of its molecular category and interaction network. Depending on the model system, it may participate in cell–cell communication, intracellular signaling, enzymatic processing, or regulation of gene expression programs. Mechanistic interpretation is often strengthened by considering upstream regulators and downstream readouts rather than relying on a single marker.
Expression and abundance of MUC-1 can vary by tissue, cell type, and physiological state. In many systems, levels are influenced by factors such as developmental stage, immune activation, metabolic status, and cellular stress. Because sample matrix and pre-analytical handling can affect measured concentrations, interpretation is typically strongest when experiments keep collection and processing consistent across groups.
Nomenclature and related terms
MUC-1 (Mucin-1) may also be referenced as Mucin-1, MUC-1, and Breast carcinoma-associated antigen DF3 in the literature or in databases. When comparing results across studies, confirm that the reported analyte refers to the same molecule, species context, and molecular form (e.g., precursor vs mature protein, or soluble vs membrane-associated forms).
Why it matters in research
- Understanding how MUC-1 relates to tumor microenvironment biology, cell proliferation and apoptosis, metastasis and invasion pathways, and angiogenesis and immune-oncology mechanisms in cancer and immunology research.
- Interpreting shifts in MUC-1 levels alongside other pathway components or complementary markers.
- Connecting molecular changes to phenotypes such as inflammation, remodeling, metabolism shifts, or cell-state transitions (context-dependent).
Molecular forms and interpretation
For some targets, isoforms, proteolytic processing, or post-translational modifications (such as phosphorylation or glycosylation) can influence function and apparent abundance. If multiple molecular forms are expected in your model, align interpretation with the form most relevant to the biological question.
Disease and translational relevance
MUC-1 has been investigated across diverse physiological and disease contexts, and changes in its abundance have been reported in areas aligned with cancer and immunology studies. These associations are interpreted as research findings rather than diagnostic or therapeutic claims, and they should be evaluated alongside model-specific covariates and study design.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone
IF: 4.7 Journal: Biomedicines Author: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, 35 Siaodong Rd., Tainan 704, Taiwan Cited Date: 2024-02-18
A novel, non-spirometric “BMP index” for predicting severe adverse outcomes in fibrosing interstitial lung diseases
IF: 3.9 Journal: Scientific Reports Author: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Cited Date: 2025-12-26
miR-152–3p facilitates cell adhesion and hepatic metastases in colorectal cancer via targeting AQP11
IF: 3.309 Journal: Pathology - Research and Practice Author: Department of Oncology, Shaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing 312000, China Cited Date: 2023-06-30
Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fbrosis receiving nintedanib: a retrospective real-world cohort study
IF: 2.813 Journal: BMC Pulmonary Medicine Cited Date: 2021-05-20
Clinical Significance of Mucins as Markers of Colon Tumor
IF: Journal: Vestnik of Vitebsk State University Cited Date: 2022-11-17